Celcuity
Celcuity Inc is an American clinical-stage biotechnology enterprise developing targeted oncology therapeutics and cellular diagnostic platforms for cancer treatment. The company advances gedatolisib, a pan-PI3K/mTOR inhibitor in pivotal Phase 3 clinical trials for HR+/HER2- advanced breast cancer and prostate cancer, alongside developing the CELsignia diagnostic platform to measure live cell signaling pathways. Principal revenue is driven through research milestone payments, strategic development partnerships, and capital raises prior to commercial authorization. Core end markets serve medical oncology centers, breast cancer clinical research institutes, and targeted prescription cancer patients globally. Celcuity holds an innovative position in the biopharmaceutical sector as a developer of dual PI3K/mTOR targeted cancer therapies and live-cell signaling diagnostics. The corporation is headquartered in Minneapolis, Minnesota, and its common stock trades on the Nasdaq Capital Market.
4 of the funds FundTelligence covers report a position in Celcuity.
- Legal name
- Celcuity Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 4
- Exposure themes
- Cancer, Treatment, Women's Health
Funds holding Celcuity
- DNB Fund Women's Health — DNB · 3.63 % (full portfolio disclosed, August 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.32 % (full portfolio disclosed, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)